Chemours (NYSE:CC) Shares Gap Up – Time to Buy?

Posted by Brenda Bartman on Nov 5th, 2026

Shares of The Chemours Company (NYSE:CC – Get Free Report) gapped up before the market opened on Tuesday. The stock had previously closed at $13.16, but opened at $14.48. Chemours shares last traded at $13.3550, with a volume of 260,401 shares traded.

Chemours News Summary

Here are the key news stories impacting Chemours this week:

Positive Sentiment: Chemours launched Faizeon two-phase liquid-cooling solutions designed to manage heat in AI data centers while improving efficiency and reducing water use. The launch positions the company to pursue demand from a growing market, though near-term revenue impact is not yet clear. Article: CC Launches Faizeon Cooling Solutions to Meet AI Data Center Demand
Neutral Sentiment: Analyst views remain mixed. Barclays maintained a Hold rating; Truist kept its Buy rating while cutting its price target to $18 from $20; and UBS kept Neutral while lowering its target to $15 from $16. The target cuts reflect more cautious expectations, despite Truist’s continued bullish rating. Article: Barclays Keeps Their Hold Rating on Chemours Article: UBS Adjusts Price Target on Chemours
Negative Sentiment: Several law firms reiterated that a securities class action has been filed for investors who bought shares from February 20 through August 4, 2026; the lead-plaintiff deadline is December 7. The allegations focus on Chemours’ 2026 EBITDA guidance and claims that distributor prebuying pulled Opteon refrigerant sales forward from 2026 into 2025. These are allegations, not findings, but the litigation adds uncertainty and reputational risk. Article: Chemours Lawsuit Lead Plaintiff Deadline Reminder
Negative Sentiment: The latest reported quarter also showed EPS of $0.21, below the $0.26 consensus and down from $0.40 a year earlier, despite revenue slightly exceeding estimates. The earnings miss reinforces concerns about profitability and the outlook. Article: Chemours Q3 2026 Earnings Call Transcript

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on CC shares. Mizuho cut shares of Chemours from an “outperform” rating to a “neutral” rating and dropped their price objective for the company from $18.00 to $15.00 in a research note on Wednesday, October 14th. The Goldman Sachs Group reissued a “neutral” rating and issued a $16.00 target price on shares of Chemours in a research note on Friday, October 9th. Royal Bank Of Canada lowered shares of Chemours from an “outperform” rating to a “sector perform” rating and set a $14.00 price target for the company. in a research report on Tuesday, October 13th. Morgan Stanley set a $18.00 price target on shares of Chemours in a research note on Monday, August 10th. Finally, UBS Group decreased their price objective on Chemours from $16.00 to $15.00 and set a “neutral” rating on the stock in a report on Wednesday. Three investment analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $17.45.

Check Out Our Latest Research Report on CC

Chemours Trading Down 7.4%

The business’s 50-day moving average price is $14.08 and its two-hundred day moving average price is $18.25. The company has a market capitalization of $1.92 billion, a P/E ratio of -12.51 and a beta of 1.47. The company has a debt-to-equity ratio of 24.25, a current ratio of 1.81 and a quick ratio of 0.88.

Chemours (NYSE:CC – Get Free Report) last released its earnings results on Monday, November 2nd. The specialty chemicals company reported $0.21 earnings per share for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.05). The business had revenue of $1.54 billion during the quarter, compared to the consensus estimate of $1.53 billion. Chemours had a negative net margin of 2.64% and a positive return on equity of 76.52%. The firm’s revenue for the quarter was up 3.0% on a year-over-year basis. During the same period last year, the business posted $0.40 EPS. As a group, analysts forecast that The Chemours Company will post 0.83 EPS for the current fiscal year.

Chemours Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 15th. Stockholders of record on Monday, November 16th will be issued a dividend of $0.0875 per share. This represents a $0.35 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date is Monday, November 16th. Chemours’s payout ratio is -34.31%.

Insider Buying and Selling

In related news, CEO Denise Dignam purchased 3,378 shares of Chemours stock in a transaction on Tuesday, August 11th. The stock was acquired at an average cost of $14.95 per share, for a total transaction of $50,501.10. Following the completion of the acquisition, the chief executive officer owned 339,916 shares of the company’s stock, valued at $5,081,744.20. This trade represents a 1.00% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Calderon Gerardo Familiar acquired 1,935 shares of the stock in a transaction on Wednesday, August 12th. The shares were acquired at an average price of $15.53 per share, for a total transaction of $30,050.55. Following the acquisition, the insider owned 58,547 shares of the company’s stock, valued at approximately $909,234.91. The trade was a 3.42% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 0.85% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. bought a new position in shares of Chemours during the 2nd quarter worth approximately $34,000. Allworth Financial LP purchased a new stake in Chemours during the second quarter valued at approximately $51,000. State of Wyoming acquired a new stake in Chemours in the second quarter valued at approximately $67,000. Sterling Capital Management LLC grew its holdings in Chemours by 839.3% in the third quarter. Sterling Capital Management LLC now owns 5,072 shares of the specialty chemicals company’s stock worth $69,000 after purchasing an additional 4,532 shares during the last quarter. Finally, Parallel Advisors LLC grew its holdings in Chemours by 15.1% in the third quarter. Parallel Advisors LLC now owns 5,926 shares of the specialty chemicals company’s stock worth $80,000 after purchasing an additional 776 shares during the last quarter. Institutional investors own 76.26% of the company’s stock.

Chemours Company Profile

(Get Free Report)

The Chemours Company (NYSE: CC) is a global chemistry company that develops and manufactures performance chemicals and advanced materials for industrial and consumer applications. The company serves customers in markets including automotive, construction, energy, electronics, healthcare, and general manufacturing.

Chemours operates through businesses focused on Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. Its products include titanium dioxide pigments used to provide whiteness and opacity in coatings, plastics, and paper; refrigerants and related thermal-management solutions; and high-performance fluoropolymers and specialty materials sold under brands such as Teflon™, Viton™, and Nafion™.

Headquartered in Wilmington, Delaware, Chemours serves customers globally through manufacturing facilities, research and development operations, and commercial activities across North America, Latin America, Europe, and Asia-Pacific.